CamptosarCompany: Pharmacia & Upjohn
Approval Status: Approved October 1998
Treatment for: Oncology
Areas: Cancer & Oncology
Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
The adverse effects of Camptosar, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
Other potential side effects include diarrhea, neutropenia among others.
Camptosar Drug Information
The Camptosar drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.